Science & Technology
Phase II- Repurposing CRH antagonists for the treatment of endometriosis
Department of Health and Human Services — National Institutes of Health
Opportunity #: 2R44HD109055-02A1
Award Ceiling
$1.2M
Award Floor
$1.2M
Close Date
Apr 30, 2027
411 days leftTotal Funding
$1.2M
Expected Awards
1
Posted Date
May 20, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-2R44HD109055-02A1
Description
SBIR Phase Phase II award: "Phase II- Repurposing CRH antagonists for the treatment of endometriosis" awarded to SUR180 THERAPEUTICS, INC. in MCALLEN, Texas. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $1,239,987. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, Women-owned businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.